Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has provided an update.
JCR Pharmaceuticals has upgraded its full-year earnings outlook for the fiscal year ended March 31, 2026, citing firm product sales and improved profitability. The company now expects net sales of ¥40.3 billion, operating profit of ¥0.5 billion, ordinary profit of ¥1.1 billion, and profit attributable to owners of parent of ¥2.1 billion, a sharp turnaround from last year’s losses.
The revised forecast represents modest top-line growth but a substantial recovery in profit, driven partly by anticipated foreign exchange gains and stable cost structures. The uplift signals operational stabilization after a weak prior year and could bolster investor confidence in JCR’s rare-disease-focused strategy, as the company leverages its expanding global footprint and specialized pipeline to sustain earnings momentum.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on next-generation therapies for rare and complex diseases. Its portfolio in Japan includes treatments for growth disorders, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia, while its pipeline targets multiple lysosomal storage and rare genetic disorders as it expands across the U.S., Europe, and Latin America.
Average Trading Volume: 548,326
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen67.32B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.